Nectar Lifesciences
Nectar Lifesciences Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Nectar Lifesciences
Start SIPNectar Lifesciences Investment Rating
-
Master Rating:
-
Nectar Lifesciences has an operating revenue of Rs. 1,524.61 Cr. on a trailing 12-month basis. An annual revenue de-growth of -7% needs improvement, Pre-tax margin of -3% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 389 | 344 | 389 | 403 | 476 |
| Operating Expenses Qtr Cr | 369 | 343 | 396 | 361 | 427 |
| Operating Profit Qtr Cr | 20 | 1 | -7 | 42 | 49 |
| Depreciation Qtr Cr | 15 | 15 | 15 | 15 | 14 |
| Interest Qtr Cr | 20 | 17 | 21 | 21 | 17 |
| Tax Qtr Cr | -2 | -8 | -10 | 2 | 6 |
| Net Profit Qtr Cr | 5 | -9 | -22 | 4 | 12 |
Nectar Lifesciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 10
- Bearish Moving Average
- ___
- 6
- 20 Day
- ₹17.08
- 50 Day
- ₹17.35
- 100 Day
- ₹18.27
- 200 Day
- ₹20.07
- 20 Day
- ₹17.06
- 50 Day
- ₹17.01
- 100 Day
- ₹18.2
- 200 Day
- ₹20.32
Nectar Lifesciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹17.22 |
| Second Resistance | ₹17.44 |
| Third Resistance | ₹17.67 |
| RSI | 53.47 |
| MFI | 66.66 |
| MACD Single Line | -0.1 |
| MACD | -0.08 |
| Support | |
|---|---|
| First Resistance | ₹16.77 |
| Second Resistance | ₹16.54 |
| Third Resistance | ₹16.32 |
Nectar Lifesciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 268,460 | 16,214,984 | 60.4 |
| Week | 170,441 | 10,845,161 | 63.63 |
| 1 Month | 157,371 | 9,535,103 | 60.59 |
| 6 Month | 492,331 | 21,268,701 | 43.2 |
Nectar Lifesciences Result Highlights
Nectar Lifesciences Synopsis
NSE-Medical-Generic Drugs
Nectar Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1524.61 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2023. Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664.| Market Cap | 388 |
| Sales | 1,525 |
| Shares in Float | 12.56 |
| No of funds | 5 |
| Yield | 0.22 |
| Book Value | 0.36 |
| U/D Vol ratio | 1 |
| LTDebt / Equity | 21 |
| Alpha | -0.16 |
| Beta | 0.62 |
Nectar Lifesciences
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 55.8% | 55.8% | 55.8% | 55.8% |
| Mutual Funds | ||||
| Foreign Portfolio Investors | 1.48% | 1.4% | 1.53% | 1.49% |
| Individual Investors | 24.47% | 24.53% | 24.34% | 24.2% |
| Others | 18.25% | 18.27% | 18.33% | 18.51% |
Nectar Lifesciences Management
| Name | Designation |
|---|---|
| Mr. Sanjiv Goyal | Chairman & Managing Director |
| Dr. Kuldip Kumar Bhasin | Independent Director |
| Dr. Indu Pal Kaur | Independent Director |
| Mr. Ajay Swaroop | Independent Director |
| Dr. Rupinder Tewari | Independent Director |
| Ms. Meena Verma | Nominee Director |
Nectar Lifesciences Forecast
Price Estimates
Nectar Lifesciences Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-26 | Audited Results & A.G.M. | |
| 2023-02-14 | Quarterly Results | |
| 2022-11-14 | Quarterly Results | |
| 2022-08-13 | Quarterly Results | |
| 2022-05-30 | Audited Results |
Nectar Lifesciences FAQs
What is Share Price of Nectar Lifesciences ?
Nectar Lifesciences share price is ₹17 As on 04 June, 2023 | 16:16
What is the Market Cap of Nectar Lifesciences ?
The Market Cap of Nectar Lifesciences is ₹388 Cr As on 04 June, 2023 | 16:16
What is the P/E ratio of Nectar Lifesciences ?
The P/E ratio of Nectar Lifesciences is -16 As on 04 June, 2023 | 16:16
What is the PB ratio of Nectar Lifesciences ?
The PB ratio of Nectar Lifesciences is 0.4 As on 04 June, 2023 | 16:16